FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170272938> ?p ?o ?g. }

• W3170272938 endingPage "1060" @default.
• W3170272938 startingPage "1060" @default.
• W3170272938 abstract "Guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) recommend intensive statin therapy and adding nonstatin therapy if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more. Compliance with guidelines is often low.To track LDL-C treatment patterns in the US over 2 years.GOULD is a prospective observational registry study involving multiple centers. Patients with ASCVD receiving any lipid-lowering therapy (LLT) were eligible. Between December 2016 and July 2018, patients were enrolled in 1 of 3 cohorts: (1) those currently receiving proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) and 2 groups not receiving PCSK9i drugs, with (2) LDL-C levels of 100 mg/dL or more or (3) LDL-C levels of 70 to 99 mg/dL. Patients had medical record reviews and telephone interviews every 6 months. Analysis was done on data collected as of October 5, 2020.The primary outcome was the change in LLT use in 2 years. Secondary outcomes included the number of LDL-C measurements, LDL-C levels, and responses to structured physician and patient questionnaires over 2 years.A total of 5006 patients were enrolled (mean [SD] age, 67.8 [9.9] years; 1985 women [39.7%]; 4312 White individuals [86.1%]). At 2 years, 885 (17.1%) had LLT intensification. In the cohorts with LDL-C levels of 100 mg/dL or more and 70 to 99 mg/dL, LLT intensification occurred in 403 (22.4%) and 383 (14.4%), respectively; statins were intensified in 115 (6.4%) and 168 (6.3%), ezetimibe added in 123 (6.8%) and 118 (4.5%), and PCSK9i added in 114 (6.3%) and 58 (2.2%), respectively. In the PCSK9i cohort, 508 of 554 (91.7%) were still taking PCSK9i at 2 years. Lipid panels were measured at least once over 2 years in 3768 patients (88.5%; PCSK9i cohort, 492 [96.1%]; LDL-C levels ≥100 mg/dL or more, 1294 [85.9%]; 70-99 mg/dL, 1982 [88.6%]). Levels of LDL-C fell from medians (interquartile ranges) of 120 (108-141) mg/dL to 95 (73-118) mg/dL in the cohort with LDL-C levels of 100 mg/dL or more, 82 (75-89) to 77 (65-90) mg/dL in the cohort with LDL-C levels of 70 to 99 mg/dL, and 67 (42-104) mg/dL to 67 (42-96) mg/dL in the PCSK9i cohort. Levels of LDL-C less than 70 mg/dL at 2 years were achieved by 308 patients (21.0%) and 758 patients (33.9%) in the cohorts with LDL-C levels of 100 mg/dL or more and 70 to 99 mg/dL, respectively, and 272 patients (52.4%) in the PCSK9i cohort. At 2 years, practice characteristics were associated with more LLT intensification (teaching vs nonteaching hospitals, 148 of 589 [25.1%] vs 600 of 3607 [16.6%]; lipid protocols or none, 359 of 1612 [22.3%] vs 389 of 2584 [15.1%]; cardiology, 452 of 2087 [21.7%] vs internal or family medicine, 204 of 1745 [11.7%] and other, 92 of 364 [25.3%]; all P < .001) and achievement of LDL-C less than 70 mg/dL (teaching vs nonteaching hospitals, 173 of 488 [35.5%] vs 823 of 2986 [27.6%]; lipid protocols vs none, 451 of 1411 [32.0%] vs 545 of 2063 [26.4%]; both P < .001; cardiology, 523 of 1686 [30.1%] vs internal or family medicine, 377 of 1472 [25.6%] and other, 96 of 316 [30.4%]; P = .003).Of patients with ASCVD, most with suboptimal LDL-C levels at baseline, only 17.1% had LLT intensification after 2 years, and two-thirds remained at an LDL-C level greater than 70 mg/dL. Further intensive efforts are needed to achieve optimal LDL-C management in patients with ASCVD." @default.
• W3170272938 created "2021-06-22" @default.
• W3170272938 creator A5001002051 @default.
• W3170272938 creator A5001262695 @default.
• W3170272938 creator A5001529279 @default.
• W3170272938 creator A5002112062 @default.
• W3170272938 creator A5002939245 @default.
• W3170272938 creator A5003283875 @default.
• W3170272938 creator A5003675274 @default.
• W3170272938 creator A5004285834 @default.
• W3170272938 creator A5004321527 @default.
• W3170272938 creator A5004865159 @default.
• W3170272938 creator A5005014227 @default.
• W3170272938 creator A5009512812 @default.
• W3170272938 creator A5010571732 @default.
• W3170272938 creator A5010681916 @default.
• W3170272938 creator A5012139970 @default.
• W3170272938 creator A5012598039 @default.
• W3170272938 creator A5012914793 @default.
• W3170272938 creator A5013350360 @default.
• W3170272938 creator A5014651013 @default.
• W3170272938 creator A5014798411 @default.
• W3170272938 creator A5015142683 @default.
• W3170272938 creator A5015334757 @default.
• W3170272938 creator A5016410787 @default.
• W3170272938 creator A5016947980 @default.
• W3170272938 creator A5017996915 @default.
• W3170272938 creator A5018284552 @default.
• W3170272938 creator A5018762211 @default.
• W3170272938 creator A5019931715 @default.
• W3170272938 creator A5020066648 @default.
• W3170272938 creator A5020758053 @default.
• W3170272938 creator A5020769275 @default.
• W3170272938 creator A5020888707 @default.
• W3170272938 creator A5021117774 @default.
• W3170272938 creator A5022102556 @default.
• W3170272938 creator A5022597555 @default.
• W3170272938 creator A5023880729 @default.
• W3170272938 creator A5024425127 @default.
• W3170272938 creator A5025134732 @default.
• W3170272938 creator A5025703869 @default.
• W3170272938 creator A5026602252 @default.
• W3170272938 creator A5028216867 @default.
• W3170272938 creator A5028863296 @default.
• W3170272938 creator A5030635903 @default.
• W3170272938 creator A5031251667 @default.
• W3170272938 creator A5032163264 @default.
• W3170272938 creator A5034738312 @default.
• W3170272938 creator A5034942823 @default.
• W3170272938 creator A5034985048 @default.
• W3170272938 creator A5035943945 @default.
• W3170272938 creator A5037369696 @default.
• W3170272938 creator A5037606710 @default.
• W3170272938 creator A5038186120 @default.
• W3170272938 creator A5038707646 @default.
• W3170272938 creator A5039401592 @default.
• W3170272938 creator A5039670868 @default.
• W3170272938 creator A5041389697 @default.
• W3170272938 creator A5044426165 @default.
• W3170272938 creator A5045310584 @default.
• W3170272938 creator A5047337825 @default.
• W3170272938 creator A5047470990 @default.
• W3170272938 creator A5051019825 @default.
• W3170272938 creator A5051212717 @default.
• W3170272938 creator A5051688731 @default.
• W3170272938 creator A5052280461 @default.
• W3170272938 creator A5052533254 @default.
• W3170272938 creator A5053310061 @default.
• W3170272938 creator A5053886250 @default.
• W3170272938 creator A5053991267 @default.
• W3170272938 creator A5054235811 @default.
• W3170272938 creator A5056045911 @default.
• W3170272938 creator A5056529507 @default.
• W3170272938 creator A5057066074 @default.
• W3170272938 creator A5057584766 @default.
• W3170272938 creator A5058332772 @default.
• W3170272938 creator A5058363516 @default.
• W3170272938 creator A5059297377 @default.
• W3170272938 creator A5059515346 @default.
• W3170272938 creator A5060129517 @default.
• W3170272938 creator A5060218009 @default.
• W3170272938 creator A5060303776 @default.
• W3170272938 creator A5060465607 @default.
• W3170272938 creator A5060676761 @default.
• W3170272938 creator A5060995910 @default.
• W3170272938 creator A5061263190 @default.
• W3170272938 creator A5061638024 @default.
• W3170272938 creator A5062337224 @default.
• W3170272938 creator A5062912312 @default.
• W3170272938 creator A5063131352 @default.
• W3170272938 creator A5063419407 @default.
• W3170272938 creator A5063497396 @default.
• W3170272938 creator A5064603944 @default.
• W3170272938 creator A5064887578 @default.
• W3170272938 creator A5066413772 @default.
• W3170272938 creator A5066868504 @default.
• W3170272938 creator A5067348293 @default.
• W3170272938 creator A5067565656 @default.

• next